SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Clinical trial NCT03085849 · COMPLETED

Trial details

NCT number: NCT03085849
Sponsor: Catherine Shu
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Extensive-stage Small Cell Lung Cancer

Start date: 2017-12-15
Primary completion: 2018-11-26
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.